V M van Praag Veroniek1, A J Rueten-Budde2, V Ho3, P D S Dijkstra4, M Fiocco5, M A J van de Sande6. 1. Department of Orthopaedic Surgery, Leiden University Medical Center, Albinusdreef 2, 2300 RC Leiden, The Netherlands. Electronic address: vmvanpraag@lumc.nl. 2. The Mathematical Institute, Leiden University, Rapenburg 70, 2311 EZ Leiden, The Netherlands. Electronic address: anjaruetenbudde@icloud.com. 3. Department of Research, Netherlands Comprehensive Cancer Organization (IKNL), Godebaldkwartier 419, 3511 DT Utrecht, The Netherlands. Electronic address: V.Ho@iknl.nl. 4. Department of Orthopaedic Surgery, Leiden University Medical Center, Albinusdreef 2, 2300 RC Leiden, The Netherlands. Electronic address: P.D.S.Dijkstra@lumc.nl. 5. The Mathematical Institute, Leiden University, Rapenburg 70, 2311 EZ Leiden, The Netherlands; Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Albinusdreef 2, 2300 RC Leiden, The Netherlands. Electronic address: M.Fiocco@lumc.nl. 6. Department of Orthopaedic Surgery, Leiden University Medical Center, Albinusdreef 2, 2300 RC Leiden, The Netherlands. Electronic address: majvandesande@lumc.nl.
Abstract
BACKGROUND: There are few studies detailing the incidence, patient outcomes and prognostic factors for chondrosarcomas (CS). Those that do exist have small sample sizes and/or use older datasets. The purpose of this study was to determine the incidence, overall survival (OS) and prognostic factors for OS of CS patients, as well as investigate the efficacy of curettage. METHODS: We analyzed data of 2186 patients diagnosed with chondrosarcomas between '89-'13 from the Netherlands Cancer Registry. The effect of risk factors on OS was assessed with a multivariate Cox regression. Median Follow-up was determined with reversed Kaplan-Meier. OS was estimated using Kaplan-Meier method. RESULTS: The relative incidence of CS was 2.88 per million citizens between '89-'96, 4.15 between '96-'04 and 8.78 between '05-'13. Most of the increase in incidence came from atypical cartilaginous tumours/grade I chondrosarcoma (ACT/CS I). The 3-, 5- and 10-years survival were, respectively, 96%, 93% and 88% for ACT/CS I, 82%, 74% and 62% for grade II CS and 38%, 31% and 26% for grade III CS. Prognostics factors significantly associated with OS were age, histological grade, year of diagnosis, tumour location and size. CONCLUSION: The incidence of CS, and especially ACT/CS I, has increased over time, which could be driven by both an ageing population and increased diagnostic imaging. With the increased number of diagnosed ACT/CS I, the number of preventative curettages of this tumour has also increased. Despite the supposed preventative character of this treatment, the incidence of high-grade CS did not decrease.
BACKGROUND: There are few studies detailing the incidence, patient outcomes and prognostic factors for chondrosarcomas (CS). Those that do exist have small sample sizes and/or use older datasets. The purpose of this study was to determine the incidence, overall survival (OS) and prognostic factors for OS of CS patients, as well as investigate the efficacy of curettage. METHODS: We analyzed data of 2186 patients diagnosed with chondrosarcomas between '89-'13 from the Netherlands Cancer Registry. The effect of risk factors on OS was assessed with a multivariate Cox regression. Median Follow-up was determined with reversed Kaplan-Meier. OS was estimated using Kaplan-Meier method. RESULTS: The relative incidence of CS was 2.88 per million citizens between '89-'96, 4.15 between '96-'04 and 8.78 between '05-'13. Most of the increase in incidence came from atypical cartilaginous tumours/grade I chondrosarcoma (ACT/CS I). The 3-, 5- and 10-years survival were, respectively, 96%, 93% and 88% for ACT/CS I, 82%, 74% and 62% for grade II CS and 38%, 31% and 26% for grade III CS. Prognostics factors significantly associated with OS were age, histological grade, year of diagnosis, tumour location and size. CONCLUSION: The incidence of CS, and especially ACT/CS I, has increased over time, which could be driven by both an ageing population and increased diagnostic imaging. With the increased number of diagnosed ACT/CS I, the number of preventative curettages of this tumour has also increased. Despite the supposed preventative character of this treatment, the incidence of high-grade CS did not decrease.
Authors: Tatiane Fonseca Faro; Allan Vinícius Martins-de-Barros; Gilberto Tenório Wanderley Fernandes Lima; André Pereira Raposo; Mariana de Albuquerque Borges; Fábio Andrey da Costa Araújo; Marianne de Vasconcelos Carvalho; Emerson Filipe de Carvalho Nogueira; José Rodrigues Laureano Filho Journal: Head Neck Pathol Date: 2021-03-22
Authors: Hendricus Nijland; Jelle Overbosch; Joris J W Ploegmakers; Thomas C Kwee; Paul C Jutte Journal: J Clin Med Date: 2021-04-22 Impact factor: 4.241
Authors: Agnieszka E Zając; Sylwia Kopeć; Bartłomiej Szostakowski; Mateusz J Spałek; Michał Fiedorowicz; Elżbieta Bylina; Paulina Filipowicz; Anna Szumera-Ciećkiewicz; Andrzej Tysarowski; Anna M Czarnecka; Piotr Rutkowski Journal: Cancers (Basel) Date: 2021-05-14 Impact factor: 6.639